Artiva CTO sells 10,366 shares to cover taxes

Artiva Biotherapeutics’ chief tech operations officer sold shares in an automatic tax sell-to-cover transaction tied to RSU vesting and remains a significant shareholder.

Rhea-AI Filing Summary

Artiva Biotherapeutics, Inc. (ARTV) reported that Chief Tech Operations Officer Christopher Horan sold 10,366 shares of common stock on September 3, 2026, at a weighted average price of $11.1555 per share. According to the company’s sell-to-cover policy, these automatic sales were made solely to satisfy tax withholding obligations from vesting restricted stock units, and Horan held 283,084 shares directly after the transaction.

Insider Trade Summary

Net Seller: 10,366 shares

Net Sell 1 txn

Insider Horan Christopher

Role Chief Tech Operations Officer

Sold 10,366 shs ($116K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	10,366	$11.1555	$116K

Holdings After Transaction: Common Stock — 283,084 shares (Direct)

Footnotes (2)

1. F1. The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
2. F2. The weighted average sale price for the transaction reported was $11.1555, and the range of prices were between $11.0301 and $11.1556. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Key Figures

Shares sold: 10,366 shares Weighted average sale price: $11.1555 per share Sale price range: $11.0301–$11.1556 per share +1 more

4 metrics

Shares sold 10,366 shares Sale of common stock on September 3, 2026

Weighted average sale price $11.1555 per share Common stock sale on September 3, 2026

Sale price range $11.0301–$11.1556 per share Range of prices for shares sold on September 3, 2026

Shares held after transaction 283,084 shares Direct ownership after September 3, 2026 sale

Key Terms

sell-to-cover policy, restricted stock units, weighted average sale price

3 terms

sell-to-cover policy financial

"The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax"

restricted stock units financial

"tax withholding obligations in connection with the vesting and release of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sale price financial

"The weighted average sale price for the transaction reported was $11.1555"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ARTV report for Christopher Horan?

Christopher Horan, Chief Tech Operations Officer, reported selling 10,366 shares of Artiva Biotherapeutics common stock on September 3, 2026, at a weighted average price of $11.1555 per share in an automatic sell-to-cover transaction for tax withholding on vested RSUs.

How many ARTV shares does Christopher Horan hold after this Form 4 transaction?

After the reported sale, Christopher Horan directly holds 283,084 shares of Artiva Biotherapeutics common stock, as stated in the Form 4 filing.

Was the ARTV insider sale by Christopher Horan discretionary or automatic?

The sale was automatic. Artiva Biotherapeutics disclosed a sell-to-cover policy, and the shares sold represent the number required to cover Horan’s tax withholding obligations from vested restricted stock units, not at his discretion.

What price range applied to Christopher Horan’s ARTV share sale?

The weighted average sale price was $11.1555 per share, with individual sale prices ranging between $11.0301 and $11.1556, according to the Form 4 footnote.

Was Christopher Horan’s ARTV sale under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not checked, and no Rule 10b5-1 plan is reported. The company instead describes the transaction as part of an automatic sell-to-cover policy for tax withholding on RSU vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 04:04 PM EDT Accepted by SEC EDGAR 09/04/2026 - 04:04 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Horan Christopher

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Tech Operations Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/03/2026		S		10,366(1)	D	$11.1555(2)	283,084	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

2. The weighted average sale price for the transaction reported was $11.1555, and the range of prices were between $11.0301 and $11.1556. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

	/s/ Andrew Cronauer, Attorney-in-Fact	09/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)